UCB S.A. UNSP.ADR 1/2 (UNC0) - Total Liabilities
Based on the latest financial reports, UCB S.A. UNSP.ADR 1/2 (UNC0) has total liabilities worth €7.29 Billion EUR (≈ $8.52 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore UNC0 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
UCB S.A. UNSP.ADR 1/2 - Total Liabilities Trend (2021–2025)
This chart illustrates how UCB S.A. UNSP.ADR 1/2's total liabilities have evolved over time, based on quarterly financial data. See UCB S.A. UNSP.ADR 1/2 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
UCB S.A. UNSP.ADR 1/2 Competitors by Total Liabilities
The table below lists competitors of UCB S.A. UNSP.ADR 1/2 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cheniere Energy Inc
NYSE MKT:LNG
|
USA | $33.64 Billion |
|
Nebius Group N.V.
NASDAQ:NBIS
|
USA | $7.84 Billion |
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-A
|
Sweden | Skr3.44 Trillion |
|
Flex Ltd
F:FXI
|
Germany | €15.70 Billion |
|
DnB ASA
OL:DNB
|
Norway | Nkr3.54 Trillion |
|
Fifth Third Bancorp
NASDAQ:FITB
|
USA | $262.93 Billion |
|
Mercedes-Benz Group AG
F:MBG
|
Germany | €161.23 Billion |
|
Shengyi Technology Co Ltd
SHG:600183
|
China | CN¥15.94 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down UCB S.A. UNSP.ADR 1/2's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of UCB S.A. UNSP.ADR 1/2.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how UCB S.A. UNSP.ADR 1/2's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for UCB S.A. UNSP.ADR 1/2 (2021–2025)
The table below shows the annual total liabilities of UCB S.A. UNSP.ADR 1/2 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €7.29 Billion ≈ $8.52 Billion |
-0.37% |
| 2024-12-31 | €7.32 Billion ≈ $8.56 Billion |
+11.49% |
| 2023-12-31 | €6.56 Billion ≈ $7.67 Billion |
-3.53% |
| 2022-12-31 | €6.80 Billion ≈ $7.95 Billion |
+16.83% |
| 2021-12-31 | €5.82 Billion ≈ $6.81 Billion |
-- |
About UCB S.A. UNSP.ADR 1/2
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthr… Read more